Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 1, 2011, Pages 31-39

  Furuse, Junji ^a   Okusaka, Takuji ^b   Bridgewater, John ^c   Taketsuna, Masanori ^d   Wasan, Harpreet ^e   Koshiji, Minori ^d   Valle, Juan ^f  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ELI LILLY AND COMPANY   (United States)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biliary tract cancer; Cisplatin; Comparison; Gemcitabine; Randomized

Indexed keywords

CISPLATIN; GEMCITABINE;

ACUTE KIDNEY FAILURE; ANOREXIA; BILIARY TRACT CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FOOT EDEMA; HUMAN; INTERSTITIAL PNEUMONIA; LETHARGY; LIVER TOXICITY; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTE; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; HUMANS; KAPLAN-MEIER ESTIMATE; TREATMENT OUTCOME;

EID: 80053132843     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.10.009     Document Type: Review

References (46)

1. Randi G., Malvezzi M., Levi F., et al. Epidemiology of biliary tract cancers: an update. Ann Oncol 2009, 20(1):146-159.
2. Kim M.J., Oh D.Y., Lee S.H., et al. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer 2008, 18(8):374.
3. Lazaridis K.N., Gores G.J. Cholangiocarcinoma. Gastroenterology 2005, 128(6):1655-1667.
4. UK National Statistics (home page: ). http://www.statistics.gov.uk/.
5. Aljiffry M., Walsh M.J., Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009, 15(34):4240-4262.
6. Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 2007, 19(8):615-617.
7. Khan S.A., Taylor-Robinson S.D., Toledano M.B., Beck A., Elliott P., Thomas H.C. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002, 37(6):806-813.
8. He X.R., Wu X.P. Difference in biological characteristics and sensitivity to chemotherapy and radiotherapy between intrahepatic and extrahepatic cholangiocarcinoma cells in vitro. Chin Med Sci J 2008, 23(1):54-59.
9. Guedj N., Martine P., Degos F., et al. Are hilar and intrahepatic cholangiocarcinomas different entities?. J Hepatol 2007, 46:242A.
10. Alberts S.R., Al-Khatib H., Mahoney M.R., et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a north central cancer treatment group phase II trial. Cancer 2005, 103(1):111-118.
11. Thongprasert S., Napapan S., Charoentum C., Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005, 16(2):279-281.
12. Knox J.J., Hedley D., Oza A., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005, 23(10):2332-2338.
13. Valle J.W., Wasan H., Johnson P., et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - the UK ABC-01 study. Br J Cancer 2009, 101(4):621-627.
14. Charoentum C., Thongprasert S., Chewaskulyong B., Munprakan S. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma. World J Gastroenterol 2007, 13(20):2852-2854.
15. Meyerhardt J.A., Zhu A.X., Stuart K., et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 2008, 53(2):564-570.
16. Doval D.C., Sekhon J.S., Gupta S.K., et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004, 90(8):1516-1520.
17. Raderer M., Hejna M.H., Valencak J.B., et al. Two consecutive phase II studies of 5-fluorouracil/leukovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999, 56(3):177-180.
18. Gallardo J.O., Rubio B., Fodor M., et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001, 12(10):1403-1406.
19. Lin M.H., Chen J.S., Chen H.H., Su W.C. A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 2003, 49(3):154-158.
20. Tsavaris N., Kosmas C., Gouveris P., et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004, 22(2):193-198.
21. Okusaka T., Ishii H., Funakoshi A., et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006, 57(5):647-653.
22. Kim S.T., Park J.O., Lee J., et al. A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006, 106(6):1339-1346.
23. Lee J., Kim T.Y., Lee M.A., et al. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol 2008, 61(1):47-52.
24. Park B.K., Kim Y.J., Park J.Y., et al. Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastroenterol Hepatol 2006, 21(6):999-1003.
25. Pasetto L.M., D'Andrea M.R., Falci C., Monfardini S. Gemcitabine in advanced biliary tract cancers. Crit Rev Oncol Hematol 2007, 61(3):230-242.
26. Valle J.W., Wasan H.S., Palmer D.D., et al. Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol 2009, 27(15s).
27. Okusaka T., Nakachi K., Fukutomi A., et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010, 103(4):469-474.
28. Ishii H., Furuse J., Yonemoto N., Nagase M., Yoshino M., Sato T. Chemotherapy in the treatment of advanced gall bladder cancer. Oncology 2004, 66:138-142.
29. Akaza H., Naito S., Usami M., Miki T., Miyanaga N., Taniai H. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: a Japanese experience. Jpn J Clin Oncol 2007, 37(3):201-206.
30. Manegold C., Drings P., von Pawel J., et al. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. Semin Oncol 1997, 24(3 Suppl. 8). S8-13-S8-17.
31. Abratt R.P., Bezwoda W.R., Falkson G., Goedhals L., Hacking D., Rugg T.A. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994, 12(8):1535-1540.
32. Felici A., Di Segni S., Milella M., et al. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. Clin Pharmacokinet 2009, 48(2):131-141.
33. Venook A.P., Egorin M.J., Rosner G.L., et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565. J Clin Oncol 2000, 18(14):2780-2787.
34. Furuse J., Okusaka T., Funakoshi A., et al. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol 2006, 36(9):552-556.
35. Zhu A.X., Meyerhardt J.A., Blaszkowsky L.S., et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010, 11(1):48-54.
36. Eckel F., Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007, 96(6):896-902.
37. Knox J.J., Hedley D., Oza A., Siu L.L., Pond G.R., Moore M.J. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret hospital experience. Ann Oncol 2004, 15(5):770-774.
38. Furuse J., Okusaka T., Ohkawa S., et al. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol 2009, 65(1):113-120.
39. Wagner A.D., Buechner-Steudel P., Moehler M., et al. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer 2009, 101(11):1846-1852.
40. Bengala C., Bertolini F., Malavasi N., et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010, 102(1):68-72.
41. Ohe Y., Ohashi Y., Kubota K., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 2007, 18:317-323.
42. Moore M.J., Winquist E.W., Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 1999, 17:2876-2881.
43. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23:4602-4608.
44. Banu E., Banu A., Fodor A., et al. Meta-analysis of randomized trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging 2007, 24(10):865-879.
45. Gemcitabine Summary of Product Characteristics (/emc/document.aspx?documentid=596&docType=SPC). http://www.medicines.org.uk/.
46. Furuse J., Okusaka T., Boku N., et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 2008, 62:849-855.